SCM
Soleus Capital Management Portfolio holdings
AUM
$1.45B
This Quarter Return
+14.15%
1 Year Return
+18.23%
3 Year Return
+274.85%
5 Year Return
+440.77%
10 Year Return
–
AUM
$736M
AUM Growth
+$736M
(+18%)
Cap. Flow
+$81.5M
Cap. Flow
% of AUM
11.07%
Top 10 Holdings %
Top 10 Hldgs %
43.9%
Holding
92
New
21
Increased
19
Reduced
26
Closed
16
Top Buys
| 1 |
Illumina
ILMN
|
$28.9M |
| 2 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$28.5M |
| 3 |
Eli Lilly
LLY
|
$26.1M |
| 4 |
Charles River Laboratories
CRL
|
$25.4M |
| 5 |
Envista
NVST
|
$15.7M |
Top Sells
| 1 |
Viridian Therapeutics
VRDN
|
$16.8M |
| 2 |
AnaptysBio
ANAB
|
$14.8M |
| 3 |
AngioDynamics
ANGO
|
$13M |
| 4 |
United Therapeutics
UTHR
|
$12.7M |
| 5 |
APEN
Apollo Endosurgery, Inc.
APEN
|
$11.7M |
Sector Composition
| 1 | Healthcare | 92.93% |
| 2 | Consumer Staples | 4.27% |
| 3 | Financials | 0.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Neuropace
NPCE
$310M
| $8.75M | 1.19% |
2,334,003
| – | – |
|
27
Vericel Corp
VCEL
$1.69B
| $8.68M | 1.18% |
+374,000
| New | +$8.68M |
|
28
Vaxcyte
PCVX
$4.17B
| $8.06M | 1.09% |
335,650
-35,000
| -9% | -$840K |
|
29
Castle Biosciences
CSTL
$673M
| $7.77M | 1.06% |
+297,840
| New | +$7.77M |
|
|
NARI
30
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $7.38M | 1% |
101,608
+29,310
| +41% | +$2.13M |
|
31
Transmedics
TMDX
$3.65B
| $7.32M | 0.99% |
175,300
-9,155
| -5% | -$382K |
|
32
Humana
HUM
$37.5B
| $6.89M | 0.94% |
+14,200
| New | +$6.89M |
|
33
Nurix Therapeutics
NRIX
$723M
| $6.57M | 0.89% |
504,144
-490,348
| -49% | -$6.39M |
|
|
INBX
34
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $6.53M | 0.89% |
+363,902
| New | +$6.53M |
|
35
Intuitive Surgical
ISRG
$158B
| $6.52M | 0.89% |
+34,800
| New | +$6.52M |
|
36
Enanta Pharmaceuticals
ENTA
$189M
| $6.38M | 0.87% |
123,014
+23,014
| +23% | +$1.19M |
|
|
APEN
37
DELISTED
Apollo Endosurgery, Inc.
APEN
| $6.27M | 0.85% |
1,137,105
-2,131,843
| -65% | -$11.7M |
|
38
Biogen
BIIB
$20.8B
| $6.19M | 0.84% |
+23,200
| New | +$6.19M |
|
39
Keros Therapeutics
KROS
$640M
| $5.49M | 0.75% |
+146,000
| New | +$5.49M |
|
40
Alnylam Pharmaceuticals
ALNY
$58.6B
| $5.4M | 0.73% |
27,000
+6,900
| +34% | +$1.38M |
|
41
Adverum Biotechnologies
ADVM
$68.2M
| $5.31M | 0.72% |
+5,587,789
| New | +$5.31M |
|
42
Axogen
AXGN
$718M
| $5.07M | 0.69% |
+424,998
| New | +$5.07M |
|
43
ESSA Pharma
EPIX
$11.2M
| $4.81M | 0.65% |
2,640,539
-1,528,260
| -37% | -$2.78M |
|
|
PVLA
44
Palvella Therapeutics, Inc. Common Stock
PVLA
$592M
| $4.76M | 0.65% |
4,134,868
| – | – |
|
45
Exact Sciences
EXAS
$9.33B
| $4.71M | 0.64% |
144,800
+25,800
| +22% | +$838K |
|
46
Enovis
ENOV
$1.75B
| $4.7M | 0.64% |
+102,100
| New | +$4.7M |
|
47
Celcuity
CELC
$2.3B
| $4.46M | 0.61% |
443,912
+25,000
| +6% | +$251K |
|
48
Xenon Pharmaceuticals
XENE
$2.99B
| $3.49M | 0.47% |
96,800
+21,800
| +29% | +$787K |
|
49
Establishment Labs
ESTA
$1.11B
| $3.42M | 0.46% |
62,620
-15,780
| -20% | -$862K |
|
|
NVRO
50
DELISTED
NEVRO CORP.
NVRO
| $3.36M | 0.46% |
+72,000
| New | +$3.36M |
|